Heron Therapeutics, Inc. (HRTX)
NASDAQ: HRTX · Real-Time Price · USD
0.8481
-0.0113 (-1.31%)
At close: May 19, 2026, 4:00 PM EDT
0.8568
+0.0087 (1.03%)
After-hours: May 19, 2026, 7:02 PM EDT

Heron Therapeutics Stock Forecast

HRTX's stock price has decreased by -56.95% in the past year and price targets may not have had time to catch up.

Stock Price Forecast

According to 3 analysts polled by S&P Global, Heron Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $3.67. The average 1-year stock price forecast is 332.73% higher than the current stock price, while the lowest is $3.00 (+253.73%) and the highest is $4.00 (+371.64%).

Price Target: $3.67 (+332.73%)
Analyst Consensus: Strong Buy
TargetLowAverageMedianHigh
Price$3.00$3.67$4.00$4.00
Change+253.73%+332.73%+371.64%+371.64%
* Price targets were last updated on Jan 9, 2026.

Analyst Ratings

The average analyst rating for Heron Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

RatingDec '25Jan '26Feb '26Mar '26Apr '26May '26
Strong Buy222222
Buy000000
Hold000000
Sell000000
Strong Sell000000
Total222222

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
HC Wainwright & Co.
HC Wainwright & Co.
Strong Buy
Reiterates
$6
Strong BuyReiterates$6+607.46%Jan 9, 2026
Needham
Needham
Strong Buy
Maintains
$4$3
Strong BuyMaintains$4$3+253.73%Aug 8, 2025
HC Wainwright & Co.
HC Wainwright & Co.
Strong Buy
Initiates
$6
Strong BuyInitiates$6+607.46%Jun 9, 2025
Needham
Needham
Strong Buy
Reiterates
$4
Strong BuyReiterates$4+371.64%Apr 11, 2025
Needham
Needham
Strong Buy
Reiterates
$4
Strong BuyReiterates$4+371.64%Feb 28, 2025
More Analyst Ratings

Financial Forecast

Revenue This Year
178.23M
from 154.90M
Increased by 15.06%
Revenue Next Year
214.61M
from 178.23M
Increased by 20.41%
EPS This Year
n/a
from -0.12
EPS Next Year
0.12
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026FY 2027
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026Dec 31, 2027
Revenue
86.35M107.67M127.04M144.29M154.90M178.23M214.61M
Revenue Growth
-2.59%24.70%17.99%13.57%7.36%15.06%20.41%
EPS
-2.24-1.67-0.80-0.09-0.12-0.12
EPS Growth
-------
Forward PE
------7.23
No. Analysts
-----54
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue20262027202820292030
High186.5M240.0M
Avg178.2M214.6M
Low169.5M188.4M

Revenue Growth

Revenue Growth20262027202820292030
High
20.4%
34.7%
Avg
15.1%
20.4%
Low
9.4%
5.7%

EPS Forecast

EPS202620272028
High0.030.12
Avg-0.12
Low-0.030.11

EPS Growth

EPS Growth202620272028
High--
Avg--
Low--
Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.